Document Type
Conference Proceeding
Publication Date
5-2022
Publication Title
Developmental Medicine and Child Neurology
Abstract
Introduction: The effects of incobotulinumtoxinA on lower limb (LL) spasticity-related pain (SRP) over multiple treatment cycles (ICs) in children/adolescents (C/As) with cerebral palsy (CP) were analyzed using pooled data from three prospective phase 3 trials.
Patients and methods: C/As aged 2–17 years with CP-associated LL spasticity received incobotulinumtoxinA for 4 ICs. SRP was assessed with the Questionnaire on Pain caused by Spasticity (QPS) using C/A- (direct or via interviewer) and parent/caregiver (P/C)-completed LL modules. The pain population included all C/As with a key QPS item score >0 at baseline; post-baseline scores of 0 indicated complete pain relief.
Results: Data from 331 C/As and 841 P/Cs with data for at least one key QPS item were included. LL general SRP was reported by 178 C/As at baseline; 35.3%/49.4% of patients treated with incobotulinumtoxinA were pain-free by week 4 of IC1/IC4 (p
Conclusion: In addition to muscle tone regulation, incobotulinumtoxinA provides sustained pain relief across multiple ICs for children with CP and LL SRP, even when they were engaged in demanding tasks.
Volume
64
Issue
Suppl 3
First Page
89
Last Page
90
Recommended Citation
Heinen F, Bonfert M, Kanovsky P, Schroeder S, Chambers H, Dabrowski E, et al. Improvements in lower limb spasticity-related pain in children/adolescents with cerebral palsy after incobotulinumtoxinA injections. Dev Med Child Neurol. 2022 May;64(Suppl 3):89-90. doi:10.1111/dmcn.15215.
DOI
10.1111/dmcn.15215
Comments
34th Annual Meeting of the European Academy of Childhood Disability, EACD 2022, May 18-21, 2022, Barcelona, Spain.
Toxins 6th Annual International Conference, July 27-30, 2022, New Orleans, LA. Toxicon. 2022 Jul;214(Suppl 1):S24-S25.